摘要
目的探讨表柔比星联合紫杉醇治疗三阴性乳腺癌的临床效果。方法将我院收治的72例三阴性乳腺癌患者随机分为试验组和对照组,每组36例。对照组给予表柔比星治疗,试验组给予表柔比星联合紫杉醇治疗。比较两组患者治疗前、后肿瘤标志物(CA125、CA153)水平、临床效果及生活质量。结果治疗后,两组患者的CA125及CA153水平明显优于治疗前,且试验组明显优于对照组(P<0.05);试验组总有效率为83.33%,明显高于对照组的61.11%(P<0.05);治疗后,两组患者的SF-36总评分均升高,且试验组明显高于对照组(P<0.05)。结论表柔比星联合紫杉醇治疗三阴性乳腺癌,可有效降低肿瘤标志物水平,具有显著的临床疗效,且能有效提高患者的生活质量。
Objective To investigate the clinical effect of epirubicin combined with paclitaxel in the treatment of triplenegative breast cancer. Methods Seventy-two cases of patients with triple-negative breast cancer were randomly divided into experimental group and control group, with 36 cases in each group. The control group was given epirubicin, and the experimental group was treated with epirubicin combined with paclitaxel. The levels of tumor markers（ CA125 and CA153）before and after treatment, clinical effects and quality of life were compared between the two groups. Results After treatment, the levels of CA125 and CA153 of the two groups were better than those before treatment, and those of the experimental group were better than the control group（P〈0.05）. The total effective rate of the experimental group was 83.33%,which was higher than 61.11% of the control group（P〈0.05）. After treatment, the total SF-36 scores of the two groups were higher than those before treatment, and that of the experimental group was higher than the control group（P〈0.05）. Conclusion Epirubicin combined with paclitaxel in the treatment of triple-negative breast cancer can reduce the levels of tumor markers, has significant clinical effect and can improve the patients＇ quality of life.
出处
《临床医学研究与实践》
2018年第5期78-79,共2页
Clinical Research and Practice
关键词
三阴性乳腺癌
表柔比星
紫杉醇
肿瘤标志物
生活质量
triple-negative breast cancer
epirubicin
paclitaxel
tumor marker
quality of life
